Share
Early treatment with inhaled budesonide shortens recovery time by a median of three days in patients with COVID-19 who are at higher risk of more severe illness and are treated in the community, finds Oxford University’s Platform Randomised Trial of Interventions against COVID-19 in Older People (PRINCIPLE) trial.
PRINCIPLE is the world’s largest Phase 3 platform randomised controlled trial to find clear evidence of an effective COVID-19 treatment for use in the community that can significantly shorten recovery time. As one of the UK Government’s national priority platform trials, findings from PRINCIPLE have potential to change how COVID-19 is treated in its early stages in non-hospital, community settings in the UK and internationally.
Share This
The FINANCIAL Early treatment with an asthma drug budesonide shortens recovery time in COVID-19 patients aged over 50 who are treated at home or in other community settings.
The Platform Randomised Trial of Interventions against COVID-19 in Older People (PRINCIPLE) trial is led by the University of Oxford. It is funded by UK Research and Innovation and the National Institute for Health Research (NIHR) through the COVID-19 Rapid Response rolling call.
It is the world’s largest Phase 3 platform randomised controlled trial to find clear evidence of an effective COVID-19 treatment for use in primary care that can significantly shorten recovery time.
The FINANCIAL - Asthma Drug Shortens Recovery Time in COVID-19 Patients at Home finchannel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finchannel.com Daily Mail and Mail on Sunday newspapers.